InnoXpo Roadshow! Audience Registration & Roadshow Application Now Open

The 2025 Spring Seasonal InnoXpo Roadshow (Virtual): China's next-generation biotech innovators, featuring diverse therapeutic modalities—including small molecules, siRNA, and bispecific antibodies—across chronic，autoimmune，inflammation and infectious diseases.

 

Company Presentations: Hear directly from Chinese biotech companies, as they present their latest advancements, clinical progress, and future directions.

 

Global Collaboration Opportunities: Gain insights into how these companies are positioning themselves for international partnerships, licensing deals, and co-development opportunities.

 

Trends in Transactions：Understand the evolving landscape of global license and the role of Chinese assets in shaping the future of chronic，autoimmune，inflammation and infectious diseases.

 

The Webinar is tailored for R&D professionals, business development executives, and investors in the global biopharma community who are looking to stay ahead of the curve in oncology innovation and explore the growing potential of China's biotech sector. Join us to connect with China's most promising biotech innovators, discover groundbreaking therapies, and explore strategic opportunities in one of the most dynamic and rapidly evolving markets in biopharma.

Get involved in Seasonal InnoXpo Roadshow

 

Audience Registration:

Register now to secure your spot and be part of this exclusive event!

https://us06web.zoom.us/webinar/register/8417465988939/WN_QTMFYn3gT0qYgube7kZcNw

 

Theme:

2025 Spring

Seasonal InnoXpo Roadshow (Virtual)

China's Next-Generation Innovators

 

Date & Time:

May 29, 8-10 AM BJT

May 28, 8-10 PM EST

May 28, 5-7 PM PST

 

Agenda:

8:00-8:10   Open Remarks

8:10-8:30   Risen Pharma

8:30-8:50   Antengene

8:50-9:10   TYK Medicines

9:10-9:30   Accropeutics

9:30-9:50   Rigerna Therapeutics

9:50-10:00  Summary

Each campany has 15mins for presentation & 5mins for Q&A

 

Host:

Sharon Yu

bioSeedin

Global Business Development Associate

 

Judge:

Alex Meltzer

Lava therapeutics

Business Development Manager

 

Risen Pharma：Risen Pharma's Innovation Pipeline: Driven by Multi-Technology Platforms

 Risen Pharma is an internationally competitive clinical-stage biotech company focused on developing and commercializing high-need, patient-accessible therapeutics. The company's integrated capabilities cover all stages of drug development, including lead identification and optimization, preclinical evaluation, clinical development, and commercialization. Risen specializes in neurodegenerative diseases like Alzheimer’s, leveraging small molecules, PROTACs, and siRNA technologies to develop a comprehensive therapeutic platform encompassing prevention through treatment. Based on strong in-house R&D capabilities, the company has advanced over 20 innovative drug candidates and built a differentiated pipeline in oncology, chronic diseases, and infectious diseases, now actively seeking global partnerships to accelerate development.

 

 

Wenbing Yu， Strategy VP of Risen Pharma

Mr. Yu Wenbing serves as the Strategy VP of Risen Pharma, overseeing financing, external collaborations, strategic planning, and market analysis. With 12 years of experience in the securities industry and over 7 years in biotech investment and financing, Mr. Yu previously held positions at China Southern Fund, Changjiang Securities, GF Securities, and Everbright Securities. Before joining Risen Pharma, he led the Investment and Financing Department at Junshi Biosciences, where he executed multiple external collaboration projects and successfully spearheaded the company’s Hong Kong IPO, STAR Market IPO, and follow-on financings in both the Hong Kong stock market and the STAR Market.

 

 

AnTenGager™ Platform: TCE 2.0 to Transform Treatment for Solid/Liquid Tumors and Autoimmune Diseases

 AnTenGager™ is an innovative 2+1 TCE platform featuring a novel proprietary CD3-binding sequence and a steric hindrance-induced masking effect. Its bivalent binding to disease-associated antigens enables enhanced recognition and clearance of cells with low target expression, while the masking effect and unique CD3 sequence optimize therapeutic efficacy while mitigating cytokine release syndrome (CRS) risks. Currently, multiple AnTenGager™ candidates are in various preclinical development stages targeting CD19 (autoimmune diseases), CDH6 (ovarian cancer, renal cancer), LY6G6D (MSS colorectal cancer), and LILRB4 (AML)，etc. The most advanced candidate, ATG-201 (CD19xCD3), is scheduled to enter clinical trials in the second half of 2025.

 

 

Ariel Guo

VP, Business Development & Assistant Chief Operating Officer

 

 

TYK Medicines：Innovative small molecule anti-cancer drugs

Focused on innovative Drugs for Cancer Treatment, with 8 clinical programs from Ph1 to Ph3 and over 10 preclinical programs, including a potential best-in-class 3rd-gen EGFR-TKI with head-to-head comparison with Osimertinib, a clinical-stage CDK2 biased inhibitor, and more.

 

 

Ming Wu，Vice President of Business Development at TYK Medicines

 Ms. Wu Ming is the Vice President of Business Development at TYK Medicines, Inc (stock code: 2410.HK).She has a multidisciplinary PhD/LLM/M.S. educational background in biochemistry, law, and management. She graduated from the University of Illinois at Urbana-Champaign, and is proficient in English, German, and French. Ms. Wu has professional qualifications and senior titles in mergers and acquisitions, law, finance, and management. With over ten years of experience in new drug research and development, intellectual property protection, licensing transactions, investment and financing, she has completed more than ten corporate acquisitions, license-out, and license-in international BD deals. She has driven the conversion of R&D outcomes into commercial value through IP and business development.

 

 

Accropeutics：Small Molecule Biotech Focused on Regulated Cell Death

 Accropeutics is dedicated to the discovery and development of innovative drugs for inflammation and autoimmune diseases. Accropeutics focuses on the "Cell Death - Inflammation" loop and has established a unique "Regulated Cell Death" drug discovery platform. Currently, the company is focusing on developing three clinical stage assets: AC-101, a RIPK2 inhibitor for IBD, AC-201, a highly selective TYK2/JAK1 inhibitor for multiple indications, and AC-003, a RIPK1 inhibitor for aGvHD.

 

 

Kenneth Gao，SVP of Corporate Development at Accropeutics

 Kenneth Gao serves as SVP of Corporate Development at Accropeutics. Prior to Accropeutics, Kenneth was VP, Head of BD and Alliance Management at Overland Pharmaceuticals, a fully integrated biopharma company backed by Hillhouse Capital. Prior to Overland, Kenneth served as Senior Director of Corporate Development and Head of China Operations at the leading infectious disease biotech Assembly Biosciences. Before Assembly, he held various managerial positions at Becton Dickinson, IMS Health, and UBS AG, focusing on biopharma transactions and corporate development. Kenneth holds an MBA from Duke University and a bachelor's degree in finance from the University at Buffalo, State University of New York.

 

 

Innovative Technology-Driven Development of Next-Generation siRNA Drugs

Rigerna Therapeutics is dedicated to the research, development, and commercialization of innovative siRNA drugs. Rooted in China with a global vision, Rigerna aims to be a leading force and transformative player in the nucleic acid pharmaceuticals sector. In response to key technological bottlenecks, IP barriers, and future development trends, Rigerna has developed core technology platforms with global independent IP rights, including RIHOST®, RICMO® and LICOD®. Leveraging various proprietary strategies, Rigerna has successfully established multiple non-hepatic in vivo delivery technologies, positioning itself as a global pioneer in non-hepatic delivery research and development. Rigerna has a profound understanding and differentiated insights in the selection of targets and indications. The liver-targeted pipeline is about to initiate Phase II clinical studies, leading the world in terms of progress. Notably, Rigerna will rapidly promote the development of a series of siRNA drugs for non-liver tissues, bringing benefits to patients.

Danny Du

COO of Rigerna

 

 

About InnoXpo Roadshow

bioSeedin is a global platform focused on pipeline transactions and PR services in the pharmaceutical field. The Seasonal InnoXpo Roadshow, organized by bioSeedin, is an online event targeting overseas pharmaceutical companies and investment institutions. It aims to facilitate cooperation and transactions between Chinese biotech companies and major pharmaceutical companies worldwide, helping them enter the international market.